epilepsy

After months of wrangling with an influential investor - the argument included calls for the resignation of the chief executive - things are looking up again at Icagen, a Durham company working on painkillers and asthma and epilepsy treatments.

At least for the moment they are.

Icagen's stock rallied Monday after the Food and Drug Administration gave Icagen the green light to start testing its epilespy drug in photosensistive patients. Until then, the FDA had had a partial clinical hold on the drug.